

Technology Advisory Committee C Interests Register

Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 [ID4038]

Publication Date: 29/03/2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Michael Chambers	Committee Member	Financial interests	Mr Chambers has co-ordinated a training programme for Roche in Real World Evidence which did not include consideration of Roche's products, and has participated in an advisory panel for Pfizer in an unrelated disease area (prostate cancer). In addition, Mr Chambers was an employee of GlaxoSmithKline from 2006 to 2015.	N/A	28/09/2022	N/A	It was agreed that his declarations would not prevent Mr Chambers from participating in discussions on this appraisal.
Stella O'Brien	Committee Member	Professional interest	Ms O'Brien is a member of the Diagnosis and Management of COVID-19 expert panel for NICE and a member of the subpanel on	N/A	28/09/2022	N/A	It was agreed that her declaration would not prevent Ms O'Brien from participating in discussions on this appraisal.

			therapeutics as part of the same committee.				
Dr Richard Nicholas	Committee Member	Financial interest	Dr Nicholas has carried out paid advisory boards for Novartis in an unrelated disease area (multiple sclerosis).	N/A	28/09/2022	N/A	It was agreed that his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal.
Professor Paul Tappenden	Committee Member	Professional interest	Professor Tappenden works for SchARR which is the Assessment Group for this appraisal. He has had no involvement in the assessment.	N/A	28/09/2022	N/A	It was agreed that his declaration would not prevent Professor Tappenden from participating in discussions on this appraisal.
Professor Iain Squire	Committee member	Professional interest	Professor Squire was an expert adviser to the NICE COVID-19 rapid guidelines committee.	N/A	18/10/2022	N/A	It was agreed that his declaration would not prevent Professor Squire from participating in discussions on this appraisal.
Professor John Watkins	Committee Member	Professional interest	Professor Watkins has worked with Roche, Merck Sharpe & Dohme and	N/A	24/01/2023	N/A	It was agreed that his declaration would not prevent Professor Watkins from participating in

			GlaxoSmithKline in the field of influenza vaccines.				discussions on this appraisal.
Dr Steven Lloyd	Committee member	Professional interest	Dr Lloyd has advised Pfizer UK informally on GP education regarding community COVID medications delivery and the operational elements of that.	N/A	24/01/2023	N/A	It was agreed that his declaration would not prevent Dr Lloyd from participating in discussions on this appraisal.
Fiona Loud	Patient expert	Indirect financial interest	Ms Loud is employed by Kidney Care UK which has received grants from GlaxoSmithKline, AstraZeneca, Pfizer and Novartis.	N/A	03/08/2022 14/01/2023	N/A	It was agreed that her declarations would not prevent Ms Loud from providing expert advice to the committee.
Dr Miranda Scanlon	Patient expert	Indirect financial and professional interests	Dr Scanlon has a volunteer role with Kidney Research UK which has received funding from AstraZeneca, Merck Sharp & Dohme and GlaxoSmithKline. Dr Scanlon is a named author in the Open Safely paper which has been presented in evidence on the comparative effectiveness of sotrovimab and molnupiravir for kidney	N/A	15/08/2022 24/01/2023	N/A	It was agreed that her declarations would not prevent Dr Scanlon from providing expert advice to the committee.

			patients on kidney replacement therapy. She did not take part in any of the analysis of data and reviewed the paper before it went to preprint.				
Sophie Wheldon	Patient expert	Indirect financial interests	Ms Wheldon is employed by Leukaemia Care which has received funding from Amgen, Insight, Novartis and Pfizer.	N/A	16/08/2023 24/01/2023	N/A	It was agreed that her declarations would not prevent Ms Wheldon from providing expert advice to the committee.
Dr Colin Brown	Clinical expert		In the year up to October 2022, Dr Brown undertook two surveys related to COVID-19 for modest remuneration, one on general trends (£5) and the most relevant one on prophylaxis and treatment for immunocompromised patients (£19). These are broad general surveys as he does not accept any surveys relating to specific products.	N/A	15/08/2022	N/A	It was agreed that her declarations would not prevent Dr Brown from providing expert advice to the committee.

Andrea Devaney	Clinical expert	Financial interest	Ms Devaney has received advisory board honorarium from GSK.	N/A	22/08/2022	N/A	It was agreed that her declarations would not prevent Ms Devaney from providing expert advice to the committee.
Dr Elizabeth Whittaker	Clinical expert	Financial and professional interests	Dr Whittaker has received honorarium from Gilead for a podcast on COVID in children. Dr Whittaker is a local PI for several COVID treatment trials in children (PK and Safety Evusheld and Paxlovid) and a member of the RECOVERY paediatric steering committee.	N/A	20/12/2022	N/A	It was agreed that her declarations would not prevent Dr Whittaker from providing expert advice to the committee.
Dr Michelle Willicombe	Clinical expert	Financial and professional interests	Dr Willicombe is the chief investigator of the MELODY study which was funded by the MRC together with a number of health charities. Dr Willicombe has been asked by AstraZeneca to speak at a conference later in the year.	N/A	13/01/2023 24/01/2023	N/A	It was agreed that her declarations would not prevent Dr Willicombe from providing expert advice to the committee.

Mandy Matthews	NHS commissioning expert	Indirect financial interest	Ms Matthews' partner has a very small number of shares in Pfizer.	N/A	23/08/2023	N/A	It was agreed that her declarations would not prevent Ms Matthews from providing expert advice to the committee.
Professor Matt Stevenson	Assessment Group representative	Financial interest	Professor Stevenson has provided paid advice to AstraZeneca in an unrelated disease area (myasthenia gravis).	N/A		N/A	It was agreed that his declaration would not prevent Professor Stevenson from representing the Assessment Group.